Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patien...

연구 요약

Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide.

Case reports in oncological medicine 학술지에 발표된 이 연구는 Mimura Y, Sanda T, Unno R 외 연구팀이 수행하였습니다.

이 연구는 'Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide.'에 대한 과학적 분석을 제공합니다.

핵심 내용

BACKGROUND: Apalutamide (Apa) is a key therapeutic agent for prostate cancer. Despite its efficacy, Apa is known to induce several drug-metabolizing enzymes including cytochrome P450 3A4 (CYP3A4), raising concerns about drug-drug interactions (DDIs). This study reports a rare case of a sustained DDI between Apa and cyclosporine (CsA)-a CYP3A4 substrate-in a patient with metastatic hormone-sensitive prostate cancer (mHSPC) and primary pure red cell aplasia (PRCA). We further investigated whether Apa could activate pregnane X receptor (PXR), a key nuclear receptor that regulates CYP3A4 expression. METHODS: With informed consent, residual blood samples were used to measure serum Apa concentration. To assess the potential of Apa in activating PXR, a reporter gene assay and a CYP3A4 mRNA induction test were performed. CASE PRESENTATION: A 75-year-old man with mHSPC was treated with Apa and leuprorelin. He developed PRCA and was administered CsA (5 mg/kg/day) on Day 1. Despite a target trough concentration (C trough) of 150-200 ng/mL, the C trough of CsA remained subtherapeutic (34 ng/mL on Day 5), even after dose escalation to 10 mg/kg/day (C trough: 66 ng/mL on Day 7), suspecting a DDI with Apa. On Day 8, Apa was discontinued and the CsA dosage was reduced to 5 mg/kg/day. The Apa concentrations measured on Days 13, 26, and 34 were 1.1, 0.15, and 0.07 μg/mL, respectively, and the C trough of CsA increased to 45, 82, and 134 ng/mL, respectively. In vitro experiments demonstrated that Apa was a strong activator of PXR and capable of inducing CYP3A4. CONCLUSION: Apa induced CYP3A4 via the PXR pathway, leading to a sustained DDI with CsA. Careful monitoring is necessary when Apa is coadministered with CYP3A4 substrates.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41743913)

📄 [전문 보기 (Markdown)](fulltext/41743913-sustained-drug-drug-interaction-between-cyclosporine-and-apa.md)